| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
260,040,000 |
| Market
Cap: |
115.77(B) |
| Last
Volume: |
1,382,430 |
Avg
Vol: |
1,612,685 |
| 52
Week Range: |
$323.57 - $446.08 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drug Manufacturers - Other |
|
Member Indexes:
|
| |
S&P COMPOSITE 1500 |
|
NASDAQ BIOTECHNOLOGY |
| |
NASDAQ COMPOSITE |
|
NASDAQ-100 |
| |
S&P 400 MIDCAP |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 543 |
| Guru Rank Value : 3 |
| Guru Occurances : 1 |
|
|
|
|
|
| |
|
Company Profile Vertex Pharmaceuticals is a biotechnology company. Co. has clinical and research programs to develop treatment of cystic fibrosis. In addition, Co. has a pipeline of investigational therapies in other diseases where it is utilizing insight into causal human biology, including sickle cell disease, beta thalassemia, APOL1-mediated kidney disease, type 1 diabetes, pain, alpha-1 antitrypsin deficiency, and muscular dystrophies. Co.'s marketed CF medicines are TRIKAFTA/KAFTRIO (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO/SYMKEVI (tezacaftor in combination with ivacaftor), ORKAMBI (lumacaftor in combination with ivacaftor) and KALYDECO (ivacaftor).
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
40,802 |
125,045 |
237,443 |
597,541 |
| Total Sell Value |
$17,242,133 |
$51,558,094 |
$92,174,963 |
$199,845,953 |
| Total People Sold |
7 |
11 |
14 |
18 |
| Total Sell Transactions |
18 |
36 |
60 |
125 |
| End Date |
2024-02-18 |
2023-11-17 |
2023-05-19 |
2022-05-19 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Lee Yuchun |
Director |
– • – |
2023-01-17 |
4 |
AS |
$312.03 |
$1,248,120 |
D/D |
(4,000) |
1,875 |
|
7% |
|
| Lee Yuchun |
Director |
– • – |
2023-01-17 |
4 |
OE |
$72.14 |
$288,560 |
D/D |
4,000 |
5,875 |
|
- |
|
| Arbuckle Stuart A |
EVP, COO |
• – – |
2022-12-06 |
4 |
A |
$0.00 |
$0 |
D/D |
12,753 |
58,031 |
|
- |
|
| Altshuler David |
EVP, Global Research and CSO |
• – – |
2022-11-15 |
4 |
AS |
$308.61 |
$10,493 |
D/D |
(34) |
36,077 |
|
3% |
|
| Altshuler David |
EVP, Global Research and CSO |
• – – |
2022-11-07 |
4 |
AS |
$299.72 |
$394,859 |
D/D |
(1,303) |
36,077 |
|
-0% |
|
| Altshuler David |
EVP, Global Research and CSO |
• – – |
2022-11-07 |
4 |
OE |
$187.53 |
$244,352 |
D/D |
1,303 |
37,380 |
|
- |
|
| Sanna Bastiano |
EVP, Cell & Genetic Therapies |
• – – |
2022-11-02 |
4 |
AS |
$310.10 |
$100,045 |
D/D |
(320) |
38,104 |
|
-3% |
|
| Sanna Bastiano |
EVP, Cell & Genetic Therapies |
• – – |
2022-11-01 |
4 |
D |
$312.84 |
$240,261 |
D/D |
(768) |
38,424 |
|
- |
|
| Bhatia Sangeeta N. |
Director |
– • – |
2022-10-24 |
4 |
AS |
$310.00 |
$192,510 |
D/D |
(621) |
4,040 |
|
-8% |
|
| Sanna Bastiano |
EVP, Cell & Genetic Therapies |
• – – |
2022-10-18 |
4 |
AS |
$300.02 |
$537,860 |
D/D |
(1,791) |
39,192 |
|
-3% |
|
| Biller Jonathan |
EVP and Chief Legal Officer |
• – – |
2022-09-19 |
4 |
A |
$0.00 |
$0 |
D/D |
5,294 |
5,294 |
|
- |
|
| Arbuckle Stuart A |
EVP, COO |
• – – |
2022-08-15 |
4 |
AS |
$300.30 |
$6,738,991 |
D/D |
(22,173) |
45,278 |
|
-6% |
|
| Arbuckle Stuart A |
EVP, COO |
• – – |
2022-08-15 |
4 |
OE |
$155.57 |
$1,022,250 |
D/D |
6,571 |
67,451 |
|
- |
|
| Kewalramani Reshma |
CEO & President |
• • – |
2022-08-15 |
4 |
AS |
$305.06 |
$3,565,846 |
D/D |
(11,689) |
99,598 |
|
-6% |
|
| Liu Joy |
SVP, General Counsel |
• – – |
2022-08-15 |
4 |
AS |
$300.26 |
$1,138,723 |
D/D |
(3,747) |
9,605 |
|
-6% |
|
| Liu Joy |
SVP, General Counsel |
• – – |
2022-08-10 |
4 |
AS |
$300.32 |
$10,812 |
D/D |
(36) |
13,352 |
|
-2% |
|
| Arbuckle Stuart A |
EVP, COO |
• – – |
2022-08-10 |
4 |
AS |
$300.32 |
$54,073 |
D/D |
(180) |
60,880 |
|
-2% |
|
| Arbuckle Stuart A |
EVP, COO |
• – – |
2022-08-10 |
4 |
OE |
$155.57 |
$9,956 |
D/D |
64 |
61,060 |
|
- |
|
| Tatsis Ourania |
EVP, Chief Reg. & Quality Off. |
• – – |
2022-08-09 |
4 |
AS |
$297.54 |
$418,557 |
D/D |
(1,400) |
46,090 |
|
-2% |
|
| Arbuckle Stuart A |
EVP, COO |
• – – |
2022-08-09 |
4 |
AS |
$300.53 |
$1,710,817 |
D/D |
(5,690) |
60,996 |
|
-2% |
|
| Arbuckle Stuart A |
EVP, COO |
• – – |
2022-08-09 |
4 |
OE |
$155.57 |
$299,628 |
D/D |
1,926 |
66,686 |
|
- |
|
| Liu Joy |
SVP, General Counsel |
• – – |
2022-08-09 |
4 |
AS |
$300.00 |
$283,800 |
D/D |
(946) |
13,388 |
|
-2% |
|
| Altshuler David |
EVP, Global Research and CSO |
• – – |
2022-08-08 |
4 |
AS |
$290.32 |
$381,469 |
D/D |
(1,304) |
36,077 |
|
-1% |
|
| Altshuler David |
EVP, Global Research and CSO |
• – – |
2022-08-08 |
4 |
OE |
$187.53 |
$244,539 |
D/D |
1,304 |
37,381 |
|
- |
|
| Bhatia Sangeeta N. |
Director |
– • – |
2022-08-08 |
4 |
AS |
$290.18 |
$181,972 |
D/D |
(621) |
4,661 |
|
-1% |
|
3271 Records found
|
|
Page 11 of 131 |
|
|
4.57 (1.04%) 
